[SCHEDULE 13G/A] MacroGenics, Inc. SEC Filing
Armistice Capital, LLC and Steven Boyd report beneficial ownership of 5,960,000 shares of MacroGenics, Inc. (MGNX), equal to 9.45% of the outstanding common stock based on 63,090,323 shares outstanding as of May 9, 2025. The filing discloses that Armistice Capital, as investment manager to Armistice Capital Master Fund Ltd. (the Master Fund), and Mr. Boyd, as managing member of Armistice Capital, each have shared voting and shared dispositive power over these shares and hold no sole voting or dispositive power. The Master Fund is the direct holder and retains the right to receive dividends or sale proceeds. This is an amendment (No. 5) to the Schedule 13G filed with the SEC.
Armistice Capital, LLC e Steven Boyd dichiarano la titolarit脿 beneficiaria di 5.960.000 azioni di MacroGenics, Inc. (MGNX), pari al 9,45% del capitale sociale in circolazione, basato su 63.090.323 azioni in essere al 9 maggio 2025. La comunicazione specifica che Armistice Capital, in qualit脿 di gestore degli investimenti di Armistice Capital Master Fund Ltd. (il Master Fund), e il sig. Boyd, in qualit脿 di membro dirigente di Armistice Capital, hanno ciascuno poteri congiunti di voto e congiunti di disposizione su tali azioni e non detengono alcun potere esclusivo di voto o di disposizione. Il Master Fund 猫 il detentore diretto e conserva il diritto di ricevere dividendi o proventi della vendita. Si tratta di un emendamento (n. 5) allo Schedule 13G depositato presso la SEC.
Armistice Capital, LLC y Steven Boyd informan la propiedad beneficiaria de 5.960.000 acciones de MacroGenics, Inc. (MGNX), equivalente al 9,45% del capital social en circulaci贸n, con base en 63.090.323 acciones en circulaci贸n a fecha de 9 de mayo de 2025. La presentaci贸n revela que Armistice Capital, como gestor de inversiones de Armistice Capital Master Fund Ltd. (el Master Fund), y el Sr. Boyd, como miembro gerente de Armistice Capital, tienen cada uno poderes compartidos de voto y disposici贸n sobre estas acciones y no poseen ning煤n poder exclusivo de voto o disposici贸n. El Master Fund es el titular directo y conserva el derecho a recibir dividendos o los ingresos de una venta. Se trata de una enmienda (n.潞 5) al Schedule 13G presentado ante la SEC.
Armistice Capital, LLC鞕� Steven Boyd電� MacroGenics, Inc. (MGNX)鞚� 5,960,000欤茧ゼ 鞁れ鞝侅溂搿� 氤挫湢頃橁碃 鞛堨潓鞚� 氤搓碃頄堨溂氅�, 鞚措姅 2025雲� 5鞗� 9鞚� 旮办 氚滍枆欤检嫕 靾� 63,090,323欤茧ゼ 旮办鞙茧 氚滍枆氤错喌欤� 齑濎垬鞚� 9.45%鞐� 頃措嫻頃╇媹雼�. 鞁犼碃靹滌棎電� Armistice Capital鞚� Armistice Capital Master Fund Ltd.(Master Fund)鞚� 韴瀽甏�毽澑鞙茧靹�, 攴鸽Μ瓿� Mr. Boyd臧� Armistice Capital鞚� 雼措嫻 鞛勳洂鞙茧靹� 臧侁皝 鞚措摛 欤检嫕鞐� 雽�頃� 瓿惦彊 鞚橁舶甓� 氚� 瓿惦彊 觳橂秳甓�鞚� 氤挫湢頃橁碃 鞛堨溂氅� 雼弲 鞚橁舶甓岇澊雮� 雼弲 觳橂秳甓岇潃 氤挫湢頃橃 鞎婋姅雼り碃 旮办灛霅橃柎 鞛堨姷雼堧嫟. Master Fund電� 歆侅爲 氤挫湢鞛愳澊氅� 氚半嫻旮� 霕愲姅 毵り皝 靾橃澋鞚� 氚涭潉 甓岆Μ毳� 氤挫湢頃╇媹雼�. 鞚措姅 SEC鞐� 鞝滌稖霅� Schedule 13G鞚� 靾橃爼靹�(氩堩樃 5)鞛呺媹雼�.
Armistice Capital, LLC et Steven Boyd d茅clarent la propri茅t茅 b茅n茅ficiaire de 5 960 000 actions de MacroGenics, Inc. (MGNX), soit 9,45 % du capital social en circulation, sur la base de 63 090 323 actions en circulation au 9 mai 2025. Le d茅p么t r茅v猫le qu'Armistice Capital, en tant que gestionnaire d'investissement d'Armistice Capital Master Fund Ltd. (le Master Fund), et M. Boyd, en tant que membre dirigeant d'Armistice Capital, disposent chacun de pouvoirs partag茅s de vote et de disposition sur ces actions et ne d茅tiennent aucun pouvoir exclusif de vote ou de disposition. Le Master Fund est le d茅tenteur direct et conserve le droit de recevoir les dividendes ou le produit d'une vente. Il s'agit d'un amendement (n掳 5) au Schedule 13G d茅pos茅 aupr猫s de la SEC.
Armistice Capital, LLC und Steven Boyd melden wirtschaftliches Eigentum an 5.960.000 Aktien von MacroGenics, Inc. (MGNX), entsprechend 9,45% des ausstehenden Stammkapitals, basierend auf 63.090.323 ausstehenden Aktien zum 9. Mai 2025. Die Einreichung legt offen, dass Armistice Capital als Investmentmanager des Armistice Capital Master Fund Ltd. (dem Master Fund) und Herr Boyd als gesch盲ftsf眉hrendes Mitglied von Armistice Capital jeweils gemeinsame Stimm- und Verf眉gungsrechte an diesen Aktien haben und keine alleinigen Stimm- oder Verf眉gungsrechte innehaben. Der Master Fund ist der unmittelbare Inhaber und beh盲lt das Recht, Dividenden oder Verkaufserl枚se zu erhalten. Dies ist eine 脛nderung (Nr. 5) der bei der SEC eingereichten Schedule 13G.
- Material disclosure of 9.45% ownership provides transparency to investors
- Clear identification of voting and dispositive power through the investment manager arrangement
- No sole voting or dispositive power by the reporting persons, indicating no direct control
- Master Fund disclaims direct beneficial ownership of the securities it holds due to the Investment Management Agreement
Insights
TL;DR Armistice and Steven Boyd hold a sizable 9.45% passive stake with shared voting/dispositive power through an investment manager arrangement.
The reporting clarifies ownership structure: the Master Fund is the record holder while Armistice Capital exercises voting and investment power under an Investment Management Agreement, and Mr. Boyd may be deemed to beneficially own the shares as managing member. The position represents a material minority stake but the absence of sole voting or dispositive power suggests the stake is managed rather than controlled. The filing is a Schedule 13G amendment, consistent with passive investor treatment.
TL;DR The filing documents a coordinated beneficial interest without control鈥攊mportant for governance and disclosure but not a control change.
Key governance implication is that shared voting/dispositive power exists, which requires disclosure but does not indicate an intent to influence control per the certification. The Master Fund's disclaimer of direct beneficial ownership due to the manager agreement is noted, and the joint filing statement confirms shared responsibility for future amendments. No changes to board composition or control are reported here.
Armistice Capital, LLC e Steven Boyd dichiarano la titolarit脿 beneficiaria di 5.960.000 azioni di MacroGenics, Inc. (MGNX), pari al 9,45% del capitale sociale in circolazione, basato su 63.090.323 azioni in essere al 9 maggio 2025. La comunicazione specifica che Armistice Capital, in qualit脿 di gestore degli investimenti di Armistice Capital Master Fund Ltd. (il Master Fund), e il sig. Boyd, in qualit脿 di membro dirigente di Armistice Capital, hanno ciascuno poteri congiunti di voto e congiunti di disposizione su tali azioni e non detengono alcun potere esclusivo di voto o di disposizione. Il Master Fund 猫 il detentore diretto e conserva il diritto di ricevere dividendi o proventi della vendita. Si tratta di un emendamento (n. 5) allo Schedule 13G depositato presso la SEC.
Armistice Capital, LLC y Steven Boyd informan la propiedad beneficiaria de 5.960.000 acciones de MacroGenics, Inc. (MGNX), equivalente al 9,45% del capital social en circulaci贸n, con base en 63.090.323 acciones en circulaci贸n a fecha de 9 de mayo de 2025. La presentaci贸n revela que Armistice Capital, como gestor de inversiones de Armistice Capital Master Fund Ltd. (el Master Fund), y el Sr. Boyd, como miembro gerente de Armistice Capital, tienen cada uno poderes compartidos de voto y disposici贸n sobre estas acciones y no poseen ning煤n poder exclusivo de voto o disposici贸n. El Master Fund es el titular directo y conserva el derecho a recibir dividendos o los ingresos de una venta. Se trata de una enmienda (n.潞 5) al Schedule 13G presentado ante la SEC.
Armistice Capital, LLC鞕� Steven Boyd電� MacroGenics, Inc. (MGNX)鞚� 5,960,000欤茧ゼ 鞁れ鞝侅溂搿� 氤挫湢頃橁碃 鞛堨潓鞚� 氤搓碃頄堨溂氅�, 鞚措姅 2025雲� 5鞗� 9鞚� 旮办 氚滍枆欤检嫕 靾� 63,090,323欤茧ゼ 旮办鞙茧 氚滍枆氤错喌欤� 齑濎垬鞚� 9.45%鞐� 頃措嫻頃╇媹雼�. 鞁犼碃靹滌棎電� Armistice Capital鞚� Armistice Capital Master Fund Ltd.(Master Fund)鞚� 韴瀽甏�毽澑鞙茧靹�, 攴鸽Μ瓿� Mr. Boyd臧� Armistice Capital鞚� 雼措嫻 鞛勳洂鞙茧靹� 臧侁皝 鞚措摛 欤检嫕鞐� 雽�頃� 瓿惦彊 鞚橁舶甓� 氚� 瓿惦彊 觳橂秳甓�鞚� 氤挫湢頃橁碃 鞛堨溂氅� 雼弲 鞚橁舶甓岇澊雮� 雼弲 觳橂秳甓岇潃 氤挫湢頃橃 鞎婋姅雼り碃 旮办灛霅橃柎 鞛堨姷雼堧嫟. Master Fund電� 歆侅爲 氤挫湢鞛愳澊氅� 氚半嫻旮� 霕愲姅 毵り皝 靾橃澋鞚� 氚涭潉 甓岆Μ毳� 氤挫湢頃╇媹雼�. 鞚措姅 SEC鞐� 鞝滌稖霅� Schedule 13G鞚� 靾橃爼靹�(氩堩樃 5)鞛呺媹雼�.
Armistice Capital, LLC et Steven Boyd d茅clarent la propri茅t茅 b茅n茅ficiaire de 5 960 000 actions de MacroGenics, Inc. (MGNX), soit 9,45 % du capital social en circulation, sur la base de 63 090 323 actions en circulation au 9 mai 2025. Le d茅p么t r茅v猫le qu'Armistice Capital, en tant que gestionnaire d'investissement d'Armistice Capital Master Fund Ltd. (le Master Fund), et M. Boyd, en tant que membre dirigeant d'Armistice Capital, disposent chacun de pouvoirs partag茅s de vote et de disposition sur ces actions et ne d茅tiennent aucun pouvoir exclusif de vote ou de disposition. Le Master Fund est le d茅tenteur direct et conserve le droit de recevoir les dividendes ou le produit d'une vente. Il s'agit d'un amendement (n掳 5) au Schedule 13G d茅pos茅 aupr猫s de la SEC.
Armistice Capital, LLC und Steven Boyd melden wirtschaftliches Eigentum an 5.960.000 Aktien von MacroGenics, Inc. (MGNX), entsprechend 9,45% des ausstehenden Stammkapitals, basierend auf 63.090.323 ausstehenden Aktien zum 9. Mai 2025. Die Einreichung legt offen, dass Armistice Capital als Investmentmanager des Armistice Capital Master Fund Ltd. (dem Master Fund) und Herr Boyd als gesch盲ftsf眉hrendes Mitglied von Armistice Capital jeweils gemeinsame Stimm- und Verf眉gungsrechte an diesen Aktien haben und keine alleinigen Stimm- oder Verf眉gungsrechte innehaben. Der Master Fund ist der unmittelbare Inhaber und beh盲lt das Recht, Dividenden oder Verkaufserl枚se zu erhalten. Dies ist eine 脛nderung (Nr. 5) der bei der SEC eingereichten Schedule 13G.
FAQ
How many MacroGenics (MGNX) shares do Armistice Capital and Steven Boyd report owning?
Do Armistice Capital or Steven Boyd have sole voting control over the reported MGNX shares?
Who is the record holder of the MacroGenics shares and who manages them?
Does the Master Fund retain economic rights to the shares?
What type of SEC filing is this and when was it signed?
